Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

1578 - Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool


08 Oct 2016


Supportive and palliative care


george Dranitsaris


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


G. Dranitsaris1, A. Molasiotis2, M. Clemons3, E. Roeland4, L. Schwartzberg5, D. Warr6, K. Jordan7, P. Dielenseger8, M.S. Aapro9

Author affiliations

  • 1 Outcomes Research, Augmentium Pharma Consulting Inc, m4k 1n2 - Toronto/CA
  • 2 School Of Nursing, Hong Kong Polytechnic University, Hong Kong/HK
  • 3 Division Of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa/CA
  • 4 Hematology & Oncology, Moores UCSD Cancer Center, La Jolla/US
  • 5 Hematology & Oncology, The West Clinic, Memphis/US
  • 6 Hematology And Medical Oncology, Princess Margaret Cancer Centre, M5G 2M9 - Toronto/CA
  • 7 Medical Oncology & Hematology, Martin Luther University of Halle, Halle/DE
  • 8 Drug Development, Institut de Cancérologie Gustave Roussy, Villejuif/FR
  • 9 Division Of Medical Oncology, Clinique de Genolier, Genolier/CH


Abstract 1578


Nausea and vomiting (N&V) remain among the most feared side effects of chemotherapy (CT). In addition to type of CT, several patient risk factors for CINV have been consistently reported in the literature. A large dataset was assembled to develop a repeated measures cycle based model that would accurately predict the risk of ≥ grade 2 CINV (≥3 vomiting episodes) over 5 days post CT.


CINV outcomes and risk factor data were obtained from 1198 patients enrolled in 1 of 5 non-interventional prospective cohort studies. For the cycle-based risk model, disease and treatment factors that were potential predictors of CINV were identified at baseline and after each cycle of CT. Factors with a p-value 


Over 4197 cycles of CT, 42.2% of patients experienced ≥ grade 2 CINV. Ten risk factors were retained in the final model (eg, age


Risk of CINV varies according to number of cycles administered, type of CT, N&V in the prior cycle, and patient factors. The application and continued refinement of this prediction tool will be an important source of patient-specific risk information that will allow the personalization of antiemetic therapy.

Clinical trial identification

Legal entity responsible for the study

Augmentium Pharma Consulting


Helsinn Healthcare


G. Dranitsaris: Consultant/Advisory Board: Helsinn Healthcare. A. Molasiotis: Honoraria: Helsinn, Tesaro, Merck, Acacia. Pharma Consulting/Advisory Role: Helsinn, Tesaro, Merck Speaker's Bureau: Helsinn, Merck. Research Funding: Helsinn, Merck, Acacia Pharma. E. Roeland: Consultant/Advisory Role: Cellceutix, Helsinn, Eisai, Teva. Speaker's Bureau: Helsinn, Teva Expert Testimony: Scripps Health. L. Schwartzberg: Consulting/Advisory Role: Eisai, Helsinn, Merck, Tesaro. Research Funding: Helsinn. D. Warr: Consulting/Advisory Role: Helsinn Speaker's Bureau: Merck. Research Funding: Merck. K. Jordan: Honoraria: MSD, Merck, Helsinn. Consulting/Advisory Role: MSD, Merck, Helsinn. P. Dielenseger: Consulting/Advisory Role: Helsinn, Roche, Pfizer, Bayer, Boehringer Ingelheim. Travel/Accomodations/Expenses: Helsinn, Bayer, Pfizer, Roche. M.S. Aapro: Honoraria/Consulting/Advisory: Sandoz, Amgen, Helsinn, Novartis, Teva, Hospira. Research Funding: Novartis, Sandoz Expert Testimony: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings